MSF at Pride: Gilead must increase global access to HIV prevention medicine HIV isn’t waiting – why is Gilead? Kate Rankin June 24 2026, 10:20am Lenacapavir is a long-acting injectable form of pre-exposure prophylaxis (PrEP) administered just twice a year that is nearly 100 percent effective in preventing people from acquiring HIV. It is especially valuable for people who often face stigma, discrimination, and exclusion from health care, including gay men and other men who have sex with men, transgender people, and sex workers.